Utilization Patterns of Pulmicort in Real Life Practice
Completed
- Conditions
- Asthma
- Registration Number
- NCT00660569
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to identify the potential issues during short and mid term utilization of Pulmicort hydro fluoroaklane (HFA) pressurized metered-dose inhaler (pMDI)and describe associated factors.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 260
Inclusion Criteria
- Asthmatic patients with a diagnose of at least 12 months of duration before study inclusion
- Patients previously treated with Pulmicort CFC who have changed their treatment to Pulmicort HFA
Read More
Exclusion Criteria
- Disability that, from investigator point of view, prevent from complying the follow up schedule
- To have participated in any clinical study in the past 6 months
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Research Site
🇪🇸Toledo, Spain